Investigation of the Effect of Food on the Bioavailability of Empagliflozin / Linagliptin Fixed Dose Combination Tablet in an Open, Randomised, Single Dose, Two Way Cross-over Study in Healthy Japanese Male Subjects
Phase of Trial: Phase I
Latest Information Update: 10 Feb 2017
At a glance
- Drugs Empagliflozin/linagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 02 Nov 2016 Status changed from active, no longer recruiting to completed.
- 05 Sep 2016 Status changed from recruiting to active, no longer recruiting.
- 01 Aug 2016 Status changed from not yet recruiting to recruiting.